Ameri Holdings

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

NAPLES, Fla., Aug. 18, 2021 /PRNewswire/ -- Enveric Biosciences   (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel therapeutic drugs to improve the quality of life for cancer patients, Chief Executive Officer, David Johnson, today is issuing an open letter to shareholders.

Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders

Whitefish, Montana--(Newsfile Corp. - August 2, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced an article covering Enveric Biosciences (NASDAQ: ENVB) and MagicMed Industries Inc.

New CBD Trials Point the Way for Enveric, MagicMed

Whitefish, MontanaWhitefish, Montana--(Newsfile Corp. - July 12, 2021) -  CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced an article covering the new relationship between Enveric Biosciences (NASDAQ: ENVB) and MagicMed Industries Inc.When two companies merge, or one is acquired by another, the reasoning behind the deal often falls into one of two categories. Either the companies are...

Enveric Bio's Acquisition of MagicMed Accentuates Strengths of Each Company

MagicMed Industries Inc merger partner Enveric Biosciences Inc (NASDAQ:ENVB) announced that it has received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its synthetic cannabidiol (CBD) glioblastoma treatment, EV101. The study is designed to investigate the safety and efficacy of synthetic CBD when administered alone or in combination with clomiphene, concurrently with the tumor medication temozolomide, to treat patients suffering from recurrent or progressive glioblastoma (GBM).

MagicMed merger partner Enveric says phase 1/2 glioblastoma trial of its synthetic CBD drug has green light from Israeli regulators

NAPLES, Fla., July 8, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that the Company has received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its lead asset, EV101, designed to investigate the safety and efficacy of synthetic cannabidiol (CBD) when administered alone or in combination with clomiphene, concurrently with temozolomide, to treat patients suffering from recurrent or progressive glioblastoma (GBM).

Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

MagicMed Industries Inc said in a corporate update that it will have more opportunities to bring new psychedelic therapies to market once its amalgamation with Enveric Biosciences Inc (NASDAQ:ENVB) closes. In the brief update, MagicMed told shareholders that the two companies are "working diligently" to finalize the definitive agreement to close their amalgamation.

MagicMed Industries updates on progress ahead of closing of Enveric Biosciences merger

Mind Medicine MindMed

Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish Buy rating to all 10.

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

Auddia

BSQUARE

Luokung Technology Corp

Micronet Enertec Technologies

Uranium Energy

VBI Vaccines

Exela Technologies

These penny stocks are showing high bullish sentiment right now; are they on your watchlist? The post 9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again

Over the past year, the world of psychedelics has been taking over as the hot area for investors as the need for alternative medicines grows at an expediential rate. There has been a sizable increase in psychedelic companies flocking to stock markets to raise capital in the interest of developing their products and one that was looking to pursue that path was MagicMed Industries Inc.

MagicMed Industries set to fly the flag for both psychedelics and cannabinoids as it agrees to acquisition by Enveric Biosciences

NAPLES, Fla., June 3, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries ("MagicMed"), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, today announced that David Johnson, Chairman and Chief Executive Officer of Enveric, and Dr. Joseph Tucker, Chief Executive Officer of MagicMed, will be participating in the following investor and industry conferences in June.

Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of MagicMed Industries Inc. to Enveric Biosciences, Inc. (“the Company”) (NasdaqCM: ENVB). Under the terms of the proposed transaction, current Enveric shareholders will own only approximately 63.4% of the combined company's common stock. KSF is seeking to determine whether the merger and the process that led to

ENVERIC BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Enveric Biosciences, Inc. - ENVB

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Enveric Biosciences, Inc. (NASDAQ: ENVB) and MagicMed Industries Inc. is fair to Enveric shareholders. Under the terms of the agreement, Enveric will issue the shareholders of MagicMed an aggregate of 9,946,969 shares of common stock of Enveric, as well as warrants, options, and restricted stock units to acquire an additional 9,039,882 shares of common stock of Enveric. Upon co

Enveric Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Enveric Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ENVB

Enveric Biosciences develops cannabinoid derived pharmaceuticals for treating cancer. Their recent acquisition of MagicMed will expand their research pipeline to psychedelic compounds and new treatments.

Enveric Biosciences Goes Psychedelic With MagicMed Acquisition

CBD-focused biotechnology company Enveric Biosciences (NASDAQ:ENVB) confirmed Monday it will acquire psychedelics company MagicMed Industries in an all-stock deal. What Happened "It's been in the works for a little while," Dr. Joseph Tucker, CEO and president of MagicMed, told Benzinga.

Another Psychedelics Company Joins 'Exclusive Nasdaq Group' With Enveric's Acquisition Of MagicMed Industries

Enveric Biosciences Inc. (NASDAQ:ENVB) said it has entered into a definitive agreement for an all-stock transaction to acquire MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications. The company said the acquisition of MagicMed will expand and complement Enveric's current pipeline of naturally occurring compounds, which is primarily focused on cannabinoids, to now include a robust portfolio of psychedelic-derived molecules.

Enveric Biosciences enters definitive agreement for an all-stock transaction to acquire MagicMed Industries

The stock price of Enveric Biosciences Inc (NASDAQ: ENVB) increased by over 6% pre-market. This is why it happened.

ENVB Stock Price: Over 6% Increase Pre-Market Explanation

NAPLES, Fla., May 24, 2021 /PRNewswire/ --  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

Centennial Resource Development

Farmmi

Finding penny stocks for June 2021? Take a look at these 3 first The post Making a Penny Stocks Watchlist for June?

Making a Penny Stocks Watchlist for June? Check These Small-Caps Out

The stock price of Enveric Biosciences Inc (NASDAQ: ENVB) increased by over 14% pre-market. This is why it happened.

Enveric Biosciences (ENVB) Stock: Over 14% Increase Pre-Market Explanation

NAPLES, Fla., May 18, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid (CBD) medicines to improve quality of life for cancer patients, today reported its financial results for the three months ended March 31, 2021.

Enveric Biosciences Reports First Quarter 2021 Financial Results

NAPLES, Fla., May 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Arash Asher, M.D.

Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board

Enveric Biosciences went public last December. The company has two pre-clinical drug candidates using cannabinoids to treat cancer and its side-effects.

Enveric Biosciences Positioned To Test Cannabinoid-Based Cancer Treatments

NAPLES, FL / ACCESSWIRE / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will present at the Planet MicroCap Showcase to be held virtually on Wednesday, April 21, 2021 at 9:00 a.m. ET. To access the live presentation, please register here.

Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st

NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has appointed Carter Ward as Chief Financial Officer, effective May 15 th, 2021.

Enveric Biosciences Appoints Carter Ward as Chief Financial Officer

NAPLES, Fla., April 1, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid (CBD)_medicines to improve quality of life for cancer patients, today reported its financial results for the year ended December 31, 2020 and provided shareholders with an update on its accomplishments in 2021 thus far.

News for Ameri Holdings Stock (ENVB)